Skip to main content

ORIGINAL RESEARCH article

Front. Microbiol.
Sec. Antimicrobials, Resistance and Chemotherapy
Volume 15 - 2024 | doi: 10.3389/fmicb.2024.1502558
This article is part of the Research Topic Emerging Antimicrobials: Sources, Mechanisms of Action, Spectrum of Activity, Combination Antimicrobial Therapy, and Resistance Mechanisms View all 3 articles

Overcoming tet(X)-harboring Tigecycline Resistance: A Study on the Efficacy of Tigecycline-Apramycin Combinations

Provisionally accepted
Juan Liu Juan Liu 1,2,3Si-Lin Zheng Si-Lin Zheng 1,2,3Jing-Jing Wu Jing-Jing Wu 1,2,3Mei Zheng Mei Zheng 1,2,3Da-Tong Cai Da-Tong Cai 1,2,3Yang Zhang Yang Zhang 1,2,3Jian Sun Jian Sun 1,2,3Xiao-Ping Liao Xiao-Ping Liao 1,2,3Yang Yu Yang Yu 1,2,3*
  • 1 National Veterinary Microbiological Drug Resistance Risk Assessment Laboratory, College of Veterinary Medicine, South China Agricultural University, Guangzhou, Guangdong Province, China
  • 2 Guangdong Provincial Key Laboratory of Veterinary Drugs Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
  • 3 South China Agricultural University, Guangzhou, Guangdong Province, China

The final, formatted version of the article will be published soon.

    The emergence of the wide variety of novel tigecycline resistance tet(X) variants, including tet(X3), tet(X4), tet(X5) and tet(X6), has raised a serious threat to global public health and posed a significant challenge to the clinical treatment of multidrugresistant bacterial infections. In this study, we evaluated the synergism of tigecycline combining with other antibiotics as a means of overcoming the tet(X)-mediated resistance in Acinetobacter spp. We found that the combinations of tigecycline with apramycin exhibited synergistic activity against tet(X)-harboring Acinetobacter spp.with FICI of 0.088. The MIC TGC decreased more than 5 times in the presence of subinhibitory levels of apramycin. The combination showed in vitro synergism in timekilling assays and in vivo therapeutic effectiveness in the mouse thigh infection model.This study shed light on the synergism of tigecycline in combination with apramycin which offers a viable therapeutic alternative for infections caused by tet(X)-harboring Acinetobacter spp.

    Keywords: tet(X)-harboring Acinetobacter spp., tigecycline, Apramycin, synergistic combination therapy, mouse thigh infection model

    Received: 27 Sep 2024; Accepted: 04 Dec 2024.

    Copyright: © 2024 Liu, Zheng, Wu, Zheng, Cai, Zhang, Sun, Liao and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Yang Yu, Guangdong Provincial Key Laboratory of Veterinary Drugs Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.